| Dermatitis, Atopic
Ebglyss vs Opzelura
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Ebglyss vs Opzelura with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOpzelura has a higher rate of injection site reactions vs Ebglyss based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Opzelura but not Ebglyss, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ebglyss
Opzelura
At A Glance
SC injection
Every 2-4 weeks
IL-13 antagonist
Topical
Twice daily
JAK inhibitor
Indications
- Dermatitis, Atopic
- Dermatitis, Atopic
- Vitiligo
Dosing
Dermatitis, Atopic 500 mg (two 250 mg injections) SC at Week 0 and Week 2, then 250 mg every 2 weeks until Week 16 or adequate clinical response; maintenance dose is 250 mg every 4 weeks SC.
Dermatitis, Atopic Apply a thin layer topically twice daily to affected areas of up to 20% body surface area; do not use with occlusive dressings; adults and pediatric patients 12 years and older: max one 60 gram tube per week or one 100 gram tube per 2 weeks; pediatric patients 2 to 11 years: max one 60 gram tube per 2 weeks.
Vitiligo Apply a thin layer topically twice daily to affected areas of up to 10% body surface area; max one 60 gram tube per week or one 100 gram tube per 2 weeks.
Contraindications
- Prior serious hypersensitivity to lebrikizumab-lbkz or any excipient of EBGLYSS
—
Adverse Reactions
Most common (>=1%) conjunctivitis, injection site reactions, herpes zoster
Serious hypersensitivity, conjunctivitis, keratitis
Most common (>=1%) - Atopic Dermatitis nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis, rhinorrhea, upper respiratory tract infection, COVID-19, application site reactions, pyrexia, white blood cell decreased
Most common (>=1%) - Nonsegmental Vitiligo application site acne, application site pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema, pyrexia
Pharmacology
Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity to IL-13, inhibiting IL-13 signaling through the IL-4Ra/IL-13Ra1 receptor complex; IL-13 is a cytokine central to Type 2 inflammation in atopic dermatitis pathogenesis.
Ruxolitinib is a JAK inhibitor that inhibits JAK1 and JAK2, which mediate signaling of cytokines and growth factors important for hematopoiesis and immune function; JAK signaling involves STAT recruitment to cytokine receptors, activation, and nuclear localization leading to modulation of gene expression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ebglyss
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Opzelura
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Ebglyss
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (4/8)
Opzelura
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Ebglyss
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Opzelura
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Ebglyss Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EbglyssView full Ebglyss profile
OpzeluraView full Opzelura profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.